Out-of-Pocket Spending for Cancer Medication, Financial Burden, and Cost Communication with Oncologists in the Last Six Months of Life in Israel.

cancer communication with oncologists cost financial burden medication out-of-pocket payment

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
30 Aug 2021
Historique:
received: 26 07 2021
revised: 23 08 2021
accepted: 26 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Honest communication between oncologists and patients is important in alleviating the financial burden of cancer care. This study explored patient-relative-oncologist communication regarding the affordability of out-of-pocket (OOP) medication and the extent to which this communication addresses itself to the families' financial burden. A cross-sectional survey was conducted among primary caregivers of deceased cancer patients. About 43% of relatives said that they and/or the patients had paid out of pocket for medications during the last six months of the patient's life. Most (73%) oncologists suggested an OOP medication without asking about financial ability, 43% hardly explained the advantages of an OOP medication, and 52% hardly explained any treatment alternatives. Older age and female gender were related to less communication about an OOP medication, and better education, greater affluence, and having private health insurance were related to more communication. About 56% of relatives said that OOP payment for medications inflicted a very heavy or heavy financial burden on patients and their households. Physicians' interest in financial ability and giving explanation lightened the burden. Given the difficulty of explaining the complex interactions of cost and clinical outcomes, oncologists need to be better educated in skills that would enable them to communicate costs more openly and should consider the cost of a treatment when prescribing it.

Identifiants

pubmed: 34574894
pii: healthcare9091120
doi: 10.3390/healthcare9091120
pmc: PMC8465014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Israel National Institute for Health Policy Research
ID : R/42/2017

Références

JAMA Oncol. 2015 Jun;1(3):273-4
pubmed: 26181165
Can J Aging. 2015 Sep;34(3):342-55
pubmed: 26218929
J Natl Cancer Inst. 2019 Feb 1;111(2):189-200
pubmed: 30085213
Inquiry. 2019 Jan-Dec;56:46958019880696
pubmed: 31583928
Oncologist. 2015 Oct;20(10):1199-204
pubmed: 26330457
Cancer. 2013 Mar 15;119(6):1257-65
pubmed: 23225522
N Engl J Med. 2011 May 26;364(21):2060-5
pubmed: 21612477
Value Health. 2017 Jan;20(1):67-76
pubmed: 28212972
Am J Obstet Gynecol. 2019 Aug;221(2):136.e1-136.e9
pubmed: 30965052
Front Public Health. 2020 Jul 24;8:329
pubmed: 32793542
J Med Person. 2013 Aug 1;11(2):
pubmed: 24349677
Soc Sci Med. 2013 Feb;78:9-16
pubmed: 23219848
J Natl Cancer Inst. 2016 Oct 20;109(2):
pubmed: 27754926
Ann Oncol. 2010 Sep;21(9):1910-1914
pubmed: 20332139
CA Cancer J Clin. 2009 Jul-Aug;59(4):250-63
pubmed: 19535791
Eur J Cancer Care (Engl). 2021 Mar;30(2):e13372
pubmed: 33191555
N Engl J Med. 2013 Oct 17;369(16):1484-6
pubmed: 24131175
J Am Geriatr Soc. 2000 Dec;48(12):1646-54
pubmed: 11129756
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Cancer. 2019 May 15;125(10):1737-1747
pubmed: 30663039
J Clin Oncol. 2009 Aug 10;27(23):3868-74
pubmed: 19581533
Oncologist. 2013;18(4):381-90
pubmed: 23442307
J Oncol Pract. 2015 Jul;11(4):308-12
pubmed: 26015459
J Oncol Pract. 2012 Jul;8(4):e50-8
pubmed: 23180999
Am J Health Syst Pharm. 2016 Jun 1;73(11):831-8
pubmed: 27126829
J Clin Oncol. 2020 Feb 1;38(4):292-301
pubmed: 31804869
Lancet Oncol. 2016 Jan;17(1):18-20
pubmed: 26670093
J Oncol Pract. 2014 Sep;10(5):332-8
pubmed: 24865220
Soc Sci Med. 2015 Apr;131:199-206
pubmed: 25464876
Cancer J. 2010 Sep-Oct;16(5):493-9
pubmed: 20890146
Support Care Cancer. 2013 Sep;21(9):2583-92
pubmed: 23649879
Med J Aust. 2015 Sep 21;203(6):244-5.e1
pubmed: 26377286
Health Policy. 2013 Apr;110(1):84-93
pubmed: 23399041
CA Cancer J Clin. 2018 Mar;68(2):153-165
pubmed: 29338071
Soc Sci Med. 2018 Dec;218:13-20
pubmed: 30316131
Ann Oncol. 2016 Aug;27(8):1423-43
pubmed: 27457309
Oncologist. 2014 Nov;19(11):1135-40
pubmed: 25273078
Med Care. 1999 Jan;37(1):27-32
pubmed: 10413389
J Clin Oncol. 2014 Apr 20;32(12):1277-80
pubmed: 24638016
Am J Manag Care. 2015 Sep;21(9):607-15
pubmed: 26618364
Soc Sci Med. 2015 Feb;126:154-63
pubmed: 25562311
Oncologist. 2014 Apr;19(4):414-20
pubmed: 24668333
JAMA Intern Med. 2014 Dec;174(12):1994-2003
pubmed: 25330167
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614

Auteurs

Aviad Tur-Sinai (A)

Department of Health Systems Management, The Max Stern Yezreel Valley College, Yezreel Valley 1930600, Israel.
School of Nursing, University of Rochester Medical Center, Rochester, NY 14642-8404, USA.

Netta Bentur (N)

Sackler Faculty of Medicine, The Stanley Steyer School of Health Professions, Tel-Aviv University, Tel Aviv-Yafo 6997801, Israel.

Damien Urban (D)

Sheba Medical Center, Department of Oncology, Tel Hashomer, Ramat Gan 5257354, Israel.

Classifications MeSH